Fulvestrant (Faslodex) for Advanced Breast Cancer
Fulvestrant (Faslodex -- AstraZeneca), an estrogen receptor antagonist given intramuscularly (IM) once a month, was recently approved by the FDA for treatment of hormone-receptor-positive metastatic breast cancer in postmenopausal women with disease progession on tamoxifen (Nolvadex, and others) or another antiestrogen....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Fulvestrant (Faslodex) for Advanced Breast Cancer
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1135
Article Code: 1135b
Date: July 22, 2002
Volume: 44
Pages: 65-66
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1135
Article Code: 1135b
Date: July 22, 2002
Volume: 44
Pages: 65-66
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)